Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide

March 24, 2022 By The ASCO Post Staff

Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal agents.

Related Content